针对脑髓母细胞瘤中Myc驱动电路的过程性转录
bioRxiv : the preprint server for biology
|April 1, 2025
概括
抑制CDK9是一种有前途的新策略,用于治疗Myc增强性脑髓母细胞瘤 (Myc-MB),这是一种高风险的儿童大脑瘤. 向CDK9破坏了关键的癌症驱动程序,为表现不佳的患者提供了潜在的新疗法.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 脑髓母细胞瘤 (MB) 是最常见的恶性儿科脑瘤.
- 高风险的MB亚型,由Myc放大 (Myc-MB) 驱动,尽管有积极的治疗,但预后不好.
- 我的瘤基因驱动着支持生存的途径,但直接准是具有挑战性的.
研究的目的:
- 使用聚合的CRISPR-Cas9屏幕来识别Myc-MB中的保存依赖性.
- 研究Myc-MB.中抑制转录辅因子,特别是CDK9的治疗潜力.
主要方法:
- 在多个独立实验室中进行CRISPR-Cas9查,以确定遗传依赖.
- 在初级患者Myc-MB样本上捕获染色体构成 (Hi-C),以映射增强剂-促进剂相互作用.
- 用CDK9/7抑制剂对*体外*和异种移植模型进行治疗,以评估对Myc驱动程序和瘤生长的影响.
主要成果:
- 八个独立的CRISPR-Cas9屏幕一致认为CDK9是Myc-MB的一个关键依赖.
- 抑制CDK9,特别是与抑制CDK7相结合时,显示出协同作用的抗瘤效应.
- 抑制CDK9/7破坏了增强剂-促进剂活性,并降低了Myc驱动的转录程序的调节,从而产生了强大的抗瘤活性.
结论:
- CDK9是Myc驱动的脑髓母细胞瘤的一个重要辅因子.
- 双CDK9/7抑制有效地向Myc-MB中的瘤转录回路.
- CDK9抑制剂代表了Myc-MB.的临床开发的一个有前途的治疗策略.
更多相关视频
相关概念视频
Induced Pluripotent Stem Cells
3.9K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
Somatic...
3.9K
Master Transcription Regulators
6.8K
Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...
6.8K
Abnormal Proliferation
4.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
Somatic to iPS Cell Reprogramming
2.2K
Reprogramming alters the gene expression in somatic cells, transforming them into induced pluripotent stem (iPS) cells over several generations. Scientists can reprogram cells by introducing genes for four transcription factors—Oct4, Sox2, Klf4, and c-Myc (OSKM) by viral or non-viral methods. These factors are also known as Yamanaka factors after Shinya Yamanaka, who first generated iPS cells using mouse skin cells. Yamanaka was awarded the Nobel Prize in Physiology or Medicine in 2012...
2.2K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K


